# Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

> **NCT00345826** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00345826
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345826, "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00345826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*